推荐产品
等级
pharmaceutical primary standard
API类
glipizide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
InChI key
ZJJXGWJIGJFDTL-UHFFFAOYSA-N
基因信息
human ... ABCC8(6833) , KCNJ11(3767)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Glipizide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
R N Brogden et al.
Drugs, 18(5), 329-353 (1979-11-01)
Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide.
H E Lebovitz
Pharmacotherapy, 5(2), 63-77 (1985-03-01)
Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpolar groups. This chemical change increases the intrinsic hypoglycemic activity of the molecule 100-fold on a weight basis compared to first-generation agents. In addition
S L Ford
The Veterinary clinics of North America. Small animal practice, 25(3), 599-615 (1995-05-01)
The oral hypoglycemic medication, glipizide, provides a viable therapeutic alternative to conventional insulin therapy with a positive therapeutic response in approximately 50% of diabetic cats with non-insulin-dependent disease. Response to glipizide therapy or lack thereof usually is evident within the
M Małecki
Przeglad lekarski, 53(9), 663-665 (1996-01-01)
The structure and effect of glipizide, the second generation derivates of sulfonylurea were described. The special role in the treatment of polymetabolic syndrome of this drug was stressed.
[Glipizide a new oral antidiabetic agent (comprehensive review)].
E Brunová
Vnitrni lekarstvi, 22(6), 595-599 (1976-06-01)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门